Gene delivery using cationic liposomes

Purpose: Cationic liposomes have been developed for gene delivery for almost 20 years, but despite extensive effort, there has been limited progress toward an effective pharmaceutical product. Their transfection efficiency remains insufficient, and most clinical trials still rely on more potent viral vectors despite viral toxicity concerns.

Hypothesis: As a review, there is no single experimental hypothesis. Central thesis: if cationic liposomes are optimized with appropriate cationic lipids, helper lipids, fusogenic agents, nuclear localisation signals, steric coatings, and targeting ligands, then transfection efficiency can be improved; however, the cationic nature and serum instability of current systems limit their suitability for parenteral gene delivery, and vaccine adjuvant applications may be more realistic.

Aims: Review progress in gene therapy and the position of cationic liposomes among clinical trial vectors. - Describe the development of liposomes as non-viral gene therapy agents. - Identify key characteristics of the most effective cationic liposomes for plasmid DNA delivery. - Outline problems converting these attributes into an effective pharmaceutical product. - Discuss alternative applications, particularly cationic lipids as vaccine adjuvants.

Delivery system: Platform: Cationic liposomes and cationic liposome–DNA complexes (lipoplexes). - Payload: Plasmid DNA; also considered for oligonucleotides and DNA/protein vaccines. - Cationic lipids: DOTMA, DOTAP, DC-Chol, DOGS, DMRIE, DDA, cationic steroid antibiotics, DOTAP dialkynoyl analogues, carbamate-linked cationic lipids. - Helper/functional lipids: DOPE as fusogenic helper lipid; cholesterol for stability; DOPC. - Additional components: lysosome-disrupting peptides (influenza-derived INF-6, INF-10), nuclear localisation signals (SV40, M9), PEG for steric stabilisation, targeting ligands such as folate, transferrin, integrin, EGF receptor, CD3, galactose/mannose, and polysaccharides. - Surface modification: PEGylation to reduce serum interactions and cytotoxicity.

Approach: Review/synthesis of literature, patent applications, and clinical trial data. Sources include PubMed, European Patent Office, and worldwide gene therapy clinical trials data. No new primary experiments. Clinical trial landscape: viral vectors remain dominant; cationic liposome systems are a minority. In vitro and in vivo literature are reviewed, with emphasis on barriers to in vivo application.

Key methods: Clinical trial vector breakdown; patent analysis; biophysical characterization of lipoplexes (size, zeta potential); transfection efficiency assays; pharmacokinetic studies of naked and lipoplexed DNA; haemolysis and serum interaction assays; cytokine/inflammatory response measurements; stability and shelf-life studies; review of cationic lipid structure–activity relationships.

Key results: Clinical translation: No FDA/EMEA-approved gene therapy product at the time. Only 2% of gene therapy trials had progressed to Phase III. Viral vectors made up ~68% of vectors used; cationic liposomes contributed >8%. The abstract notes ~85% of clinical trials continued to rely on viral delivery. - Pharmacokinetics: Naked DNA was rapidly eliminated from plasma, with ~60% of the dose recovered in the liver within ≤1.5 min; intact plasmid DNA had a bloodstream half-life of <5 min and was undetectable after 1 h. Cationic lipoplexes were also eliminated rapidly and accumulated mainly in lung and liver. - Helper lipid effects: DOPE enhanced in vitro transfection but could reduce in vivo activity; cholesterol improved in vivo activity and bilayer rigidity. - Toxicity: Cationic lipids with quaternary amine head groups (DOTAP, DOTMA, DDA) inhibited protein kinase C and were highly cytotoxic; tertiary amine lipids (e.g., DC-Chol) were less toxic. Carbamate-linked lipids were stable at neutral pH but degraded in endosomes. - Stability: Liposome–DNA complexes aggregated within hours and transfection efficiency decreased; stable formulations were maintained for 90 days at −20°C and 4°C with octylglucoside/dialysis, but not at ambient temperature or 37°C. Carbamoyl linker lipids remained stable for ≥2 months at 4°C. PEG-PE, polyamines, and lyophilisation improved shelf life. - Inflammatory responses: Dose- and route-dependent; CpG motifs in plasmid DNA contributed; removal reduced but did not eliminate responses.

Interpretation: Non-viral gene delivery still relies heavily on cationic lipids and polymers. Much optimization is based on in vitro studies that ignore serum interactions, so optimized physicochemical properties are lost in vivo before reaching target cells. Unless the cationic nature is masked, cationic lipid–based gene delivery systems are generally unsuitable for parenteral administration due to rapid reticuloendothelial uptake. However, this cationic nature may be advantageous for vaccine adjuvant applications, which may ultimately prove a better use for cationic lipids.

Limitations: This is a review, not a primary study. No successful clinical cationic liposome gene therapy product had been developed. Key limitations include serum instability, rapid clearance, cationic lipid toxicity, inflammatory responses, poor long-term stability, and low transfection efficiency. The review is dated 2006, so clinical and formulation advances after that time are not covered.